Archives of neurology · 2009
Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jacob Anu, Matiello Marcelo, Weinshenker Brian G, Wingerchuk Dean M, Lucchinetti Claudia, Shuster Elizabeth, Carter Jonathan, Keegan B Mark, Kantarci Orhun H, Pittock Sean J
Аннотация
BACKGROUND: Neuromyelitis optica (NMO) is the first inflammatory autoimmune demyelinating disease of the central nervous system for which a specific antigenic target has been identified; the marker autoantibody NMO-IgG specifically recognizes the astrocytic water channel aquaporin 4. Current evidence strongly suggests that NMO-IgG may be pathogenic. Since disability accrues incrementally related to attacks, attack prevention with immunosuppressive therapy is the mainstay of preventing disability.
OBJECTIVE: To evaluate the efficacy and safety of mycophenolate mofetil therapy in NMO spectrum disorders.
DESIGN: Retrospective case series with prospective telephone follow-up.
SETTING: Mayo Clinic Health System. Patients Twenty-four patients with NMO spectrum disorders (7 treatment-naive). Intervention Mycophenolate mofetil (median dose of 2000 mg per day).
MAIN OUTCOME MEASURES: Annualized relapse rates and disability (Expanded Disability Status Scale).
RESULTS: At a median follow-up of 28 months (range, 18-89 months), 19 patients (79%) were continuing treatment. The median duration of treatment was 27 months (range, 1-89 months). The median annualized posttreatment relapse rate was lower than the pretreatment rate (0.09; range, 0-1.5; and 1.3; range, 0.23-11.8, respectively; P < .001). Disability stabilized or decreased in 22 of 24 patients (91%). One patient died of disease complications during follow-up. Six patients (25%) noted adverse effects during treatment with mycophenolate.
CONCLUSION: Mycophenolate is associated with reduction in relapse frequency and stable or reduced disability in patients with NMO spectrum disorders.
OBJECTIVE: To evaluate the efficacy and safety of mycophenolate mofetil therapy in NMO spectrum disorders.
DESIGN: Retrospective case series with prospective telephone follow-up.
SETTING: Mayo Clinic Health System. Patients Twenty-four patients with NMO spectrum disorders (7 treatment-naive). Intervention Mycophenolate mofetil (median dose of 2000 mg per day).
MAIN OUTCOME MEASURES: Annualized relapse rates and disability (Expanded Disability Status Scale).
RESULTS: At a median follow-up of 28 months (range, 18-89 months), 19 patients (79%) were continuing treatment. The median duration of treatment was 27 months (range, 1-89 months). The median annualized posttreatment relapse rate was lower than the pretreatment rate (0.09; range, 0-1.5; and 1.3; range, 0.23-11.8, respectively; P < .001). Disability stabilized or decreased in 22 of 24 patients (91%). One patient died of disease complications during follow-up. Six patients (25%) noted adverse effects during treatment with mycophenolate.
CONCLUSION: Mycophenolate is associated with reduction in relapse frequency and stable or reduced disability in patients with NMO spectrum disorders.
Предметные рубрики MeSH
AdultAgedAnti-Inflammatory Agents, Non-SteroidalAquaporin 4Disability EvaluationDrug-Related Side Effects and Adverse ReactionsFemaleFollow-Up StudiesHumansImmunoglobulin GImmunosuppression TherapyInterviews as TopicMaleMiddle AgedMycophenolic AcidNeuromyelitis OpticaProspective StudiesRetrospective StudiesSecondary PreventionTreatment Outcome